Merck has clear vision to eye disease assets with $3B EyeBio

Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech.

Related Keywords

New Jersey , United States , David Guyer , Tony Adamis , Akorn Pharmaceuticals , Merck Co , Chief Scientific Officer Tony Adamis ,